TREATMENT GUIDE
Food allergy treatments in development
Only treatments in phase 2 or 3
The nearest: the peanut patch
Waiting has a cost
Reviewed by Hunter Smith, MD · Last checked October 2026 · Checked every three months
IN SHORT
Several immunotherapy-like treatments are being tested for food allergy, however they may take years to reach patients.
The nearest is the peanut patch. Its maker asked the FDA for approval in late 2026, which means a decision no earlier than 2027.
One thing to know: waiting has a cost. The evidence for potential lasting benefit from food allergy immunotherapy is strongest in the youngest children, so a family holding out for something better may miss the time in which treatment works best.
What is being tested
This list only contains treatments that are in Phase 2 or Phase 3 of development.
Viaskin Peanut patch (DBV)
Phase 3 finished
WHAT IT IS
A daily skin patch delivering peanut protein. Nobody eats the food. Intended to retrain tolerance.
WHAT HAS BEEN SHOWN
Both trials met their targets in toddlers and in children aged 4 to 7. Full figures and what they mean are on our peanut patch page.
WHAT TO WATCH FOR
An FDA filing in late 2026, for ages 4 to 7, is pending. A decision would follow in 2027 at the earliest.
Viaskin Milk patch (DBV)
Phase 2 finished
WHAT IT IS
A daily skin patch delivering milk protein. Nobody eats the food. Intended to retrain tolerance similar to the peanut patch
WHAT HAS BEEN SHOWN
Found improved milk tolerance in children 2-11 years old. Most participants had some type of mild adverse event, mostly skin irritation.
WHAT TO WATCH FOR
Awaiting Phase 3 data
PVX108 (Aravax)
Phase 2 running
WHAT IT IS
A regularly repeated injection (about every 2-4 weeks) of seven short synthetic fragments of peanut protein components. Too small to trigger a reaction. Intended to retrain tolerance.
WHAT HAS BEEN SHOWN
Phase 1 in 67 adults found no serious adverse events and immune changes pointing toward tolerance. No results yet against a placebo.
WHAT TO WATCH FOR
Phase 2 headline results expected during 2026.
Peanut Sublingual Immunotherapy Tablet (ALK)
Phase 1 and 2 finished with preliminary data released
WHAT IT IS
A daily tablet containing peanut protein placed under the tongue to help retrain tolerance.
WHAT HAS BEEN SHOWN
Participants 4-65 years of age with peanut allergy were assessed for tolerability. Most participants tolerated the tablets well with the most common side effect being mild-moderate mouth itching.
WHAT TO WATCH FOR
Phase 3 trial is expected to start late 2026.
Remibrutinib
Phase 2 finished
WHAT IT IS
A tablet swallowed twice daily to reduce how severe a reaction is. It could work against several foods at the same time. The medicine was approved in fall 2025 for adults with chronic hives.
WHAT HAS BEEN SHOWN
Phase 2 in adults with peanut allergy showed improvement in the amount of peanut tolerated and adults tolerated the medicine well.
WHAT TO WATCH FOR
Phase 3 trial ongoing and looking at peanut, milk, and egg allergies.
If you want to join a trial
Trials need volunteers and joining one is a way to get access to something years before it is approved. It is also a commitment, and there is usually a real chance of being put in the group that receives no active treatment.
Start with your allergist.
They will know what is enrolling nearby and whether your child would qualify.
Public listings are at clinicaltrials.gov.
It is run by the US National Library of Medicine and lists trials that are recruiting.
You should never pay to take part in a clinical trial.
If someone asks you for money to join one, that is the signal to walk away.
Questions to ask your allergist
Given my child’s age, is it sensible to wait for something new, or to start with what exists?
Are you involved in any trials, or do you refer to a center that is?
If something is approved in two years, could my child switch to it after starting something else now?
KEEP READING